Compare Enbridge Inc (ENB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Novo Nordisk A/S — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Enbridge Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Novo Nordisk A/S for 116 Days on average.
| ENB | NVO | |
|---|---|---|
Market Cap | $103.38B | $165.31B |
Volume | 3,684,305 | 11,432,838 |
Sector | Energy | Health |
52-Week High | $58.04 | $63.98 |
52-Week Low | $45.23 | $35.29 |
Typical Hold Time | 91 Days | 116 Days |
Enterprise Value | $185.39B | $179.56B |
Dividend Yield | 6.02% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.54, up 1.42% on the day, with a bearish technical signal from moving averages. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.46 surpassing the $0.43 estimate. The company maintains a solid dividend yield, with a $0.97 payment scheduled for September 2026. Revenue grew to $65.19B in 2025, and net income reached $7.49B, though profit margins have fluctuated. Analyst consensus is mixed, with a $61.63 price target suggesting significant upside from current levels.
The outlook for ENB is cautiously optimistic, supported by earnings beats and a strong dividend, but tempered by bearish technicals and rising debt levels. Investment appeal lies in its stable cash flows and growth backlog, while risks include interest rate sensitivity and execution of capital projects. The stock presents a value opportunity if it can navigate macroeconomic headwinds and maintain operational performance.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
